Cargando…
The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma
Multiple myeloma (MM) is a plasma cell malignancy that is often driven by chromosomal translocations. In particular, patients with t(4;14)-positive disease have worse prognosis compared to other MM subtypes. Herein, we demonstrated that t(4;14)-positive cells are highly dependent on the mevalonate (...
Autores principales: | Longo, Joseph, Smirnov, Petr, Li, Zhihua, Branchard, Emily, van Leeuwen, Jenna E., Licht, Jonathan D., Haibe-Kains, Benjamin, Andrews, David W., Keats, Jonathan J., Pugh, Trevor J., Trudel, Suzanne, Penn, Linda Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359767/ https://www.ncbi.nlm.nih.gov/pubmed/32665698 http://dx.doi.org/10.1038/s41375-020-0962-2 |
Ejemplares similares
-
Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins
por: van Leeuwen, Jenna E., et al.
Publicado: (2022) -
MMSET is the key molecular target in t(4;14) myeloma
por: Mirabella, F, et al.
Publicado: (2013) -
Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing
por: Chow, Signy, et al.
Publicado: (2022) -
The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis
por: Oliveira, Vanessa, et al.
Publicado: (2019) -
Dr.VAE: improving drug response prediction via modeling of drug perturbation effects
por: Rampášek, Ladislav, et al.
Publicado: (2019)